Ambria Dermatology AB was sold after Aqilion (legacy PULS) had run the project for five years in 2009. Ambria developed a technological platform to prolong the lifecycle of dermatological and hygiene products. The profits were three times the invested capital.
DuoCort Pharma developed Plenadren® (a medication for treating adrenal insufficiency) and was sold in 2011 to an American pharmaceutical company (ViroPharma, now known as Shire). DuoCort Pharma was started and run by Aqilion for seven years and the final value of the sale was more than SEK 1 billion, or 12 times the invested capital.
LIDDS AB was listed on the Nasdaq First North (Stockholm, Sweden) in 2014.
AcuCort AB was listed on Spotlight Stock Market (previously known as Aktietorget) in Stockholm, Sweden in 2017. Aqilion has remained the main shareholder with 27% of shares.